Loading…
Ken GriffinReduced
Citadel Advisors · Q2 2026
$2.79M
480.15K shares · 0.0% of portfolio
Wave Life Sciences, Inc.
Wave Life Sciences, Inc. (WVE) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in Cambridge, United States and has 317 employees. The company is worth $660.11M. Revenue was $42.73M in fiscal 2025, down 60.5% from the year before. It reported a net loss of $204.38M. The share price is 84.6% below its 52-week high of $21.73. 8 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Lee Ainslie (Maverick Capital), at $59.72M. In that quarter, 5 of them opened or added to the position and 1 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▼ -19.7% over 5Y.
today you would have $681.92▼ -31.8%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 11 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $17.00 | $12.37 | $5.05 | $7.00 | $3.14 | $7.87 | $8.02 | $42.04 | $35.10 | $26.15 | $15.95 | |
| P/S | 76.5x | 76.5x | 17.6x | 5.5x | 188.2x | 4.7x | 19.5x | 17.4x | 99.7x | 252.4x | 414.6x | 2261.5x |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| IMMXImmix Biopharma, Inc. | $7.98 | — | 2.5x | 0.00% | -34.18% | $661.57M |
| ACHVAchieve Life Sciences Inc | $6.38 | — | — | 0.00% | -844.99% | $657.79M |
| PHARPharming Group N.V. | $9.36 | 72.0x | 2.5x | 0.00% | 3.65% | $662.48M |
| LXRXLexicon Pharmaceuticals Inc | $1.49 |
| P/B | 6.1x | 6.3x | 9.1x | 15.6x | — | 5.9x | 4.7x | 4.4x | 19.6x | 7.0x | 4.6x | 2.2x |
| EPS | -$1.21 | -$0.70 | -$0.54 | -$2.05 | -$2.36 | -$3.82 | -$5.72 | -$5.06 | -$3.85 | -$2.44 | -$1.83 |
| Profit margin | -1017.43% | -478.33% | -89.57% | -50.76% | -4434.72% | -298.42% | -746.68% | -1211.52% | -1017.43% | -2619.57% | -3748.15% | -12631.58% |
| ROE | -109.09% | -39.43% | -46.30% | -145.12% | — | -376.16% | -181.10% | -303.83% | -199.94% | -73.05% | -41.35% | -12.51% |
Median of the years shown; P/E years above 200x are left out.
| — |
| 3.8x |
| 0.00% |
| -40.21% |
| $662.98M |
| SLDBSolid Biosciences Inc. | $6.19 | — | 1.7x | 0.00% | -65.50% | $663.72M |
| DSGNDesign Therapeutics, Inc. | $10.49 | — | 3.3x | 0.00% | -34.13% | $656.48M |